- Home
- ADIL vs SNGX Comparison
ADIL vs SNGX Comparison
Compare ADIL & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADIL | SNGX |
|---|---|---|
| Founded | 2010 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 5.9M |
| IPO Year | 2017 | 2006 |
Fundamental Metrics
Financial Performance| Metric | ADIL | SNGX |
|---|---|---|
| Price | $2.71 | $0.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $37.50 | $6.00 |
| AVG Volume (30 Days) | 1.2M | ★ 11.3M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.03 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $119,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $0.28 |
| 52 Week High | $5.17 | $6.23 |
Technical Indicators
Market Signals| Indicator | ADIL | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 57.22 | 40.23 |
| Support Level | $1.53 | $0.28 |
| Resistance Level | $3.67 | $0.41 |
| Average True Range (ATR) | 0.47 | 0.05 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 16.34 | 7.77 |
Price Performance
Historical ComparisonAbout ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).